Cellebrite DI Ltd. CLBT
10.79
(0.58)
(5.10%)
as of 25 Sep
- Market cap
- $2.9B
- P/E
- 45.0×
Follow CLBT
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 12.42% | 16.44% | 19.10% | 20.46% |
+8 more TTM periods Free account |
|
| 6.60% | 8.65% | 9.61% | 10.43% | ||
ROIC |
36.53% | 48.58% | 87.90% | 0.00% | |
Return on Tangible Assets |
23.50% | 33.61% | 34.29% | 20.41% | |
Average Days of Receivables |
78.62 | 53.48 | 80.55 | 83.42 | |
Free Cash Flow per Share |
(0.08) | 0.01 | 0.05 | 0.56 | |
Free Cash Flow |
(20.04) | 2.69 | 12.86 | 137.51 | |
Capital Expenditures |
(177.60) | (169.86) | (160.68) | (15.19) | |
Piotroski F-Score |
4.00 | 4.00 | 4.00 | 5.00 | |
| Other line items | |||||
Cash ROIC |
16.07% | 18.36% | 18.84% | 15.69% | |
Accounts Receivable Turnover |
5.04 | 6.45 | 5.08 | 4.61 | |
Accounts Payable Turnover |
1.01 | 1.04 | 0.93 | 1.08 | |
Inventory Turnover |
9.78 | 9.71 | 9.09 | 7.96 | |
Average Days of Payables |
396.20 | 412.47 | 427.67 | 367.58 | |
Days of Inventory on Hand |
34.94 | 34.30 | 36.92 | 43.18 | |
Tax Rate |
(0.22) | (0.15) | (0.14) | (0.09) | |
Research and Development Expense of Revenue |
25.24% | 24.67% | 23.94% | 24.04% | |
Selling, General and Administrative Expense of Revenue |
46.86% | 46.44% | 46.28% | 46.45% | |
Share Based Compensation of Revenue |
11.07% | 10.17% | 9.44% | 9.25% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
2.68 | 2.40 | 2.22 | 2.00 | |
Depreciation/Fixed assets |
0.84 | 0.57 | 0.43 | 0.34 | |
Capex/Depreciation |
(8.65) | (12.82) | (16.92) | (2.01) | |
Revenue per Share |
2.08 | 2.01 | 1.97 | 1.87 | |
Operating CF per Share |
0.64 | 0.70 | 0.72 | 0.63 | |
Capex per Share |
(0.72) | (0.69) | (0.66) | (0.06) | |
Capex to Sales |
0.35 | 0.34 | 0.34 | 0.03 | |
Net Profit Margin |
11.43% | 14.48% | 16.47% | 16.74% |
Columns are period end dates